Sanofi Says Next-gen Covid Booster Shot Has Potential Against Main Variants

KONTAN.CO.ID - PARIS. French drugmaker Sanofi said on Monday an upgraded version of the Covid-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.
While the two companies' first experimental Covid shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.
Ini Artikel Spesial
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan.
Sudah berlangganan? MasukBerlangganan dengan Google
Gratis uji coba 7 hari pertama. Anda dapat menggunakan akun Google sebagai metode pembayaran.
Kontan Digital Premium Access
Business Insight, Epaper Harian + Tabloid, Arsip Epaper 30 Hari
Rp 120.000
Business Insight
Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi bisnis dan investasi pilihan